在接受同种异体干细胞移植的老年急性髓性白血病患者中，使用克拉屈滨/低剂量盐酸阿糖胞苷/威奈托克的低强度疗法与强化化疗相比效果良好

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia2016 · 68 citations
2. 2Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial2021 · 31 citations
3. 3Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy2022 · 48 citations
4. 4Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission2009 · 886 citations
5. 5Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial2022 · 1 citations